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Abstract
Background: Cardiovascular disease is the most common cause of death and risk prediction formulae such as the 
Framingham Risk Score have been developed to easily identify patients at high risk that may require therapeutic 
interventions.
Discussion: Using cardiovascular risk formulae at a population level to estimate and compare average cardiovascular 
risk among groups has been recently proposed as a way to facilitate surveillance of net cardiovascular risk and target 
public health interventions. Risk prediction formulas may help to compare interventions that cause effects of different 
magnitudes and directions in several cardiovascular risk factors, because these formulas assess the net change in risk 
using easily obtainable clinical variables. Because of conflicting data estimates of the incidence and prevalence of 
cardiovascular disease, risk prediction formulae may be a useful tool to estimate such risk at a population level.
Summary: Although risk prediction formulae were intended on guiding clinicians to individualized therapy, they also 
can be used to ascertain trends at a population-level, particularly in situations where changes in different 
cardiovascular risk factors over time have different magnitudes and directions. The efficacy of interventions that are 
proposed to reduce cardiovascular risk impacting more than one risk factor can be well assessed by these means.
Background
Prediction of CV risk
As cardiovascular (CV) disease corresponds to the most
common cause of death in the United States with esti-
mates exceeding one million deaths annually [1], esti-
mates of individual and population-based CV risk are of
paramount importance. CV risk prediction formulae and
tables are decision tools that allow the identification of
patients at high risk of CV disease. These tools allow early
interventions by providers to recommend lifestyle modi-
fication or drugs to control modifiable CV risk factors,
including hypertension, diabetes, smoking, dyslipidemia
and obesity.
Several CV risk prediction formulae are used in clinical
practice worldwide. In the United States, the modified
F r a m i n g h a m  R i s k  S c o r e  ( F R S )  i s  t h e  m o s t  c o m m o n l y
used tool [2], and has been adapted for use in diverse
populations in other parts of the world. Other tools
include the Prospective Cardiovascular Munster Heart
Study (PROCAM) [3], the Systematic Coronary Risk
Evaluation system (SCORE) [4], United Kingdom Pro-
spective Diabetes Study (UKPDS) [5] tool for diabetics,
the Reynolds Risk Score [6,7] and more recently, one
which includes obesity as a variable (NHANES) [8].
The variables included in the FRS include age, sex,
smoking status, diabetes status, cholesterol, and blood
pressure values. These variables are routinely available in
patients receiving medical care, particularly in a primary
care setting, as routine screening for hypertension, smok-
ing status, dyslipidemia, and fasting hyperglycemia are
part of normative preventative health measures [9]. With
such information clinicians could either use gender-spe-
cific risk score tables in assigning points that can translate
into a given 10-year CV risk, or use electronic or web-
based risk calculators http://www.framinghamheart-
study.org/risk/coronary.html to calculate such risks. The
purpose of risk stratification is to identify and treat
patients that may be at higher long-term CV risk in a sim-
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ple and cost-efficient manner. This risk tool has an
acceptable area under the receiver operating curve of
roughly 75% [10]. Most of these tools, particularly the
FRS have been validated in many different populations
and ethnic groups and recalibrated appropriately [11-14],
making it a well-known risk index that allows comparison
of risks across different population groups. However,
there are distinct ethnic populations, particularly in those
with higher prevalences of metabolic syndrome where
recalibration is often challenging and its applicability may
be limited [11,13-15].
The advent of other markers of CV disease, including
high sensitivity C-reactive protein (HS-CRP), homo-
cysteine, lipoprotein (a), or coronary calcification scores
[16-18], have been shown to predict incident coronary
disease but they add little prognostic value to standard
risk formulae and their incorporation into present clinical
practice has been challenging. High sensitivity CRP is
associated with an increased risk of future cardiovascular
disease, diabetes and even hypertension [16,19,20]. Yet
studies have shown a minimal incremental value of add-
ing new biomarkers to existing prediction models in a
recent study by the Framingham group [21]. Interestingly,
there is emerging evidence in potentially using CRP, par-
ticularly using the Reynolds Risk Score, to re-classify
intermediate risk subjects into a high risk category for
potential interventions [6,7,22]. In addition, detection of
subclinical coronary artery disease with screening tests
like CT to measure coronary calcium has been a topic of
a recent debate. The AHA Consensus document which
outlined the likely benefit of using this modality to risk-
stratify intermediate risk patients to either high or low
categories depending on the score [23]. This group did
not recommend its use in either low or high-risk patients.
The utility of biomarkers for the detection of subclinical
coronary disease for risk stratification may be limited in
individuals believed to be at high CV risk, who for some
reason have an FRS that is not too high, but these bio-
markers are possibly useful in those with intermediate
risk.
Discussion
Limitations of studies assessing the prevalence of coronary 
artery disease
The assessment of disease burden in the population is of
critical importance for public health officials and health
care policy makers. In the case of CV disease burden,
there are some challenges to estimate changes in inci-
dence and prevalence of CV disease. Although some epi-
demiologic studies have shown a downtrend in CV
mortality in the USA [24-26], the trend in incident CV
disease has demonstrated conflicting results [27]. Some
of the problems are the change in diagnostic criteria for
myocardial infarction, changes in screening patterns and
improved diagnostic modalities to detect coronary and
vascular disease in the subclinical phase, factors that will
directly affect the likelihood to diagnose a person with
CV disease.
Thus, estimates of change in CV risk may be meaning-
ful and valid alternatives to assess trends in CV burden in
the population. If CV risk prediction formulae have been
shown to be accurate and useful in estimating risk at the
individual level, they may also provide estimates of CV
risk at the population level. The total CV risk in a popula-
tion can be obtained by calculating the average CV risk
using individual-based information on CV risk factors
from nationally representative data like the National
Health and Nutrition surveys (NHANES) and weighting
it for standardized demographics [28].
The value of CV risk prediction formulae to estimate
risk at the population level is also justified because CV
risk factors have been constantly changing in different
magnitude and direction over the past 30 years. For
example, mean cholesterol values showed a downward
trend soon after statins became widely available, but then
flattened years later [29]. A similar trend was observed
for cigarette smoking [29,30], while other factors like obe-
sity [31,32] and diabetes mellitus [33-35] have become
more prevalent. Furthermore, changes have not been uni-
form for both sexes and across different age strata.
Because these major CV risk factors provide different
strengths of risk for incident myocardial infarction [36],
the only way to know the net trend in risk for incident CV
disease in a given country may be by using risk prediction
formulae.
A recent analysis examining changes in the predicted
10-year CV risk in the US, demonstrated that the esti-
mated net risk for CV disease in the US population
decreased between 1976 to 1980 and 1988 to 1994, but
has changed minimally from 1988 to 1994 and from 1999
to 2004, particularly in women and middle-aged people
[28]. These data have enormous public health implica-
tions, and suggest that the gain in primary prevention of
CV disease that occurred from 1976 to 1980 and 1990 to
1994 has levelled off during the last time period, despite
the discovery and implementation of effective treatment
modalities in managing dyslipidemia and hypertension
[37-39], national anti-smoking campaigns [40] and efforts
related to primordial prevention. This study confirmed
the utility of using simple risk-prediction tables or equa-
tions to project future CV risk and assess the trajectory of
given trends. In addition, the same principle of usability
of risk scores to assess population trends in predicted
cardiovascular health may be also applied to newer scores
attempting to predict lifetime CV risks [41]. In this study,
aimed at predicting lifetime CV risk, the majority of par-
ticipants (56%) were classified as having a low short-term
risk using the FRS. Indeed, using newer risk predictionBatsis and Lopez-Jimenez BMC Medicine 2010, 8:29
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rules that go beyond the typical 10-year horizon may
have greater meaning for public health and public policy.
Policy makers should be actively analyzing existing epide-
miologic datasets in order to assess ongoing trends in net
CV risk and to determine the areas with the highest yield
to reduce CV risk in the population and plan for public
health interventions.
Estimation of net change in CV risk for interventions that 
affect risk factors in different ways
Although pharmacologic interventions for either hyper-
tension or dyslipidemia can induce a significant reduc-
tion in CV risk, lifestyle interventions that affect several
risk factors are also a critical step in managing CV risk.
Different lifestyle interventions lead to different levels of
change in lipids, blood pressure, body weight and blood
glucose, and therefore the net change in cardiovascular
risk after implementing these interventions is rarely
known. The comparison of different strategies in reduc-
ing CV risk is also problematic when they affect different
CV risk factors in different ways. For example, very low
fat diets can induce a reduction in body weight, blood
pressure, and total and LDL cholesterol, but may also
cause a reduction in HDL cholesterol. Mediterranean
diets may improve weight, blood pressure and lipids, but
cause HDL cholesterol to rise, although their effect on
LDL may be more modest [42]. Diets like the dietary
approaches to stop hypertension (DASH) also affect lip-
ids, but their major benefit comes from blood pressure
reduction, with limited effect on fasting glucose [43].
Thus, to ascertain which diet has a more favorable effect
on CV events it is necessary to estimate and compare the
net change in CV risk. Surprisingly, there have been lim-
ited studies examining the impact of either dietary modi-
fication or physical activity on 10-year predicted CV risk.
Multiple studies have examined the impact of CV risk
factor reduction following pharmacologic interventions,
but very few have ascertained the net change in CV risk.
Specifically, changes in Framingham risk with lifestyle
intervention have not been extensively studied. One
study demonstrated modest changes in FRS for primary
prevention of CV disease using a health report card with
counselling on cardiovascular risk factors [44]. The larg-
est prospective trial to date recently evaluated a multi-
component lifestyle intervention demonstrating a relative
risk of 0.88 (0.83 to 0.94; P < 0.001) in patients undergo-
ing an established lifestyle recommendation for blood
pressure control (reduction in salt, weight loss, and phys-
ical activity) with a DASH diet, and 0.86 (0.81 to 0.91; P <
0.001) in the established lifestyle alone using the FRS [45].
Estimation of events prevented with specific interventions
Cardiovascular (CV) risk prediction formulae provide an
estimated value that corresponds to the likelihood of
developing CV events over a period of time. Thus, it
could be argued that interventions that reduce the esti-
mated risk would also result in a reduction in CV events.
Two studies were published examining change in CV risk
using both the FRS but also a risk score derived from the
National Health and Nutrition Examination Surveys
[8,46]. Using the FRS, the relative risk reduction for a car-
diovascular event in patients managed surgically for obe-
sity was 50%, while all-cause mortality was reduced by
44.2% using the NHANES risk score. The 10-year risk did
not change from 30% at baseline to 30% at follow-up in
non-operative controls [8]. Such an intervention repre-
sents an estimate of 4 overall deaths and 16 cardiovascu-
lar events prevented by bariatric surgery per 100 patients
compared with the non-operative group.
Other studies, using bariatric surgery cohorts, have
used the FRS to estimate the CV risk reduction, and have
demonstrated a relative risk reduction of 33% with an
absolute reduction in FRS score from 6% to 4% (P  <
0.001) [47]. Recently, two studies have examined the
impact of bariatric surgery on long-term patient out-
comes whose results parallel the outcomes predicted in
the above studies. The Swedish Obesity study, whose
study population consists primarily of vertical banded
gastroplasty patients, had prospective patient data and
the adjusted HR for death in the surgical group was 0.71,
suggesting a 29% less risk of death at 10-years in the sur-
gical group [48]. In the study by Adams et al. [49], the
adjusted long-term mortality was 40% lower in the surgi-
cal group with 7.1 years of follow-up. These results sug-
gest that prediction tools like the FRS can potentially be
practically used to estimate actual number of events in
patients at higher cardiometabolic risk. We do caution,
though, that further studies are needed to validate the use
of such formulae in such select populations which may
not be representative of the cohorts that the original for-
mulae were developed from, to additionally incorporate
disease-specific or procedure-specific complications in
these assessments.
Shortcomings of current risk prediction tools
The FRS relies on traditional risk factors including hyper-
tension, diabetes, smoking status, and dyslipidemia.
Other risk factors like family history of premature CV
disease, obesity, high sensitivity CRP, inflammatory
cytokines and lifestyle are not incorporated in present
risk formulae. By omitting these risk factors, the current
risk prediction formulas may underestimate CV risk in
some individuals, particularly those at intermediate CV
risk [6,7,22].
Accurate risk equations are often translated into risk
t a b l e s  t o  f a c i l i t a t e  c l i n i c a l  d e c i s i o n  m a k i n g .  T a b l e s  a r e
used clinically to differentiate between high and low risk
patients, allowing the implementation of preventative
strategies. Thresholds are often used to categorize con-
tinuous variables as normal or abnormal or using differ-Batsis and Lopez-Jimenez BMC Medicine 2010, 8:29
http://www.biomedcentral.com/1741-7015/8/29
Page 4 of 6
ent level proportional risk using a points system. By doing
so, some prognostic information in extreme values is dis-
regarded despite the linear or near linear association
between CV risk factors and CV events. Variables whose
incremental risk is proportional or exponential to its
level, for instance, with hypertension or elevated LDL, the
dichotomization of variables according to a given thresh-
old leads to similar risks being applied to values that
barely exceed the threshold with those that are far
beyond the threshold. Conversely, values that are slightly
below the threshold are often treated as normal, which
leads to inaccuracies.
Sometimes, therapeutic interventions may have unin-
tended consequences on other diseases, such as the
increased mortality rates observed in diabetes with inten-
sive insulin regimens [50]. The intent of such interven-
tions is to improve cardiovascular risk factors which may
not translate in a reduction in clinical events. In addition,
other interventions, such as sodium restriction have
larger effects on CV disease than its impact on blood
pressure alone and modest effects yield greater than
expected changes, which extend beyond such clinical
markers [51]. This may limit the use of such prediction
rules in forecasting trends in CV events using informa-
tion related to changes in CV risk factors. Future scores
should acknowledge and address these limitations.
However, further research is needed to be able to apply
these risk prediction tools, intended for individualized
patients, to translate into larger population-based health
interventions. As the degree of cardiovascular and overall
morbidity and mortality changes, the necessity of recali-
brating existing risk equations is needed. For instance,
the Framingham equation was based on a population of
patients decades ago whose characteristics are much dif-
ferent than those existing nowadays [2]. In addition, with
the development of new biomarkers and enhanced
understanding of the pathophysiologic of atherosclerosis,
future formulae will likely incorporate measures of fac-
tors representing different mechanistic pathways beyond
the current approach that addresses traditional risk fac-
tors only. Hence, clinicians and public health officials
need to be aware of the population-level estimates of dis-
ease burden to assess absolute risk. Furthermore, calibra-
tion needs to occur to allow application of risk algorithms
to other population and/or ethnic groups. More impor-
tantly, risk prediction equations target preventative care
to those asymptomatic patients at intermediate or high
risk, but still roughly a third of all CV events occur in
subjects labeled as low risk by common equations.
Summary
Risk prediction formulas were originally created for
proper CV risk stratification at the individual level. They
are recommended to guide medication therapy and iden-
t i fy  p e o p l e  i n  w h o m  i n t e rv e n t i o n s  m a y  b e  m o r e  c o s t -
effective. The use of such risk prediction formulas in
assessing risk trends at a population level may also be
used to predict changes in net CV risk, potentially pre-
dicting changes in the incidence of CV disease and there-
fore may be used to preliminarily assess the trend in CV
disease risk and burden in a particular population. These
formulas can also be used to assess net benefit in CV risk
reduction for interventions that can affect several CV risk
factors such as diets with different macronutrient compo-
sitions that affect different CV risk factors, in different
directions and magnitudes. Population-based estimates,
though, can be guided by such formulae, understanding
the caveat that not only calibration is needed when pre-
dicting risk in different populations, but also to consider
the shortcomings due to imperfect prediction of clinical
outcomes.
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